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Microglia are important for central nervous system (CNS) homeostasis and first to
respond to tissue damage and perturbations. Microglia are heterogeneous cells; in
case of pathology, microglia adopt a range of phenotypes with altered functions.
However, how these different microglia subtypes are implicated in CNS disease is
largely unresolved. Multiple sclerosis (MS) is a chronic demyelinating disease of the
CNS, characterized by inflammation and axonal degeneration, ultimately leading to
neurological decline. One way microglia are implicated in MS is through stimulation of
remyelination. They facilitate efficient remyelination by phagocytosis of myelin debris.
In addition, microglia recruit oligodendrocyte precursor cells (OPCs) to demyelinated
areas and stimulate remyelination. The development of high-resolution technologies
to profile individual cells has greatly contributed to our understanding of microglia
heterogeneity and function under normal and pathological conditions. Gene expression
profiling technologies have evolved from whole tissue RNA sequencing toward single-
cell or nucleus sequencing. Single microglia proteomic profiles are also increasingly
generated, offering another layer of high-resolution data. Here, we will review recent
studies that have employed these technologies in the context of MS and their respective
advantages and disadvantages. Moreover, recent developments that allow for (single)
cell profiling while retaining spatial information and tissue context will be discussed.
Keywords: multiple sclerosis, microglia, heterogeneity, spatial, sequencing
Abbreviations: ALS, amyotrophic lateral sclerosis; ATAC-seq, assay for transposase-accessible chromatin sequencing;
BBB, blood–brain barrier; CC, corpus callosum; CHIP-seq, chromatin immunoprecipitation sequencing; CITE-seq, cellular
indexing of transcriptomes and epitopes by sequencing; CNS, central nervous system; CyTOF, cytometry by time-of-
flight; EAE, experimental-autoimmune encephalomyelitis; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescent-
activated cell sorting; FF, fresh frozen; FPE, formalin-fixed paraffin-embedded; FISH, fluorescent in situ hybridization;
FISSEQ, fluorescent in situ sequencing; GM, gray matter; GML, gray matter lesion; GO, Gene ontology; GWAS, genome-
wide association study; HD, Huntington’s disease; HE, hematoxylin and eosin; ICP, inductively coupled argon plasma;
IHC, immunohistochemistry; ISH, in situ hybridization; ISS, in situ sequencing; LCM, laser capture microdissection;
LPC, lysolecithin; LPS, lipopolysaccharide; MERFISH, multiplexed error-robust fluorescent in situ hybridization; MRI,
magnetic resonance imaging; MS, multiple sclerosis; NAGM, normal-appearing gray matter; NAWM, normal-appearing
white matter; OPC, oligodendrocyte precursor cell; PMD, postmortem delay; qPCR, quantitative polymerase chain reaction;
RCA, rolling circle amplification; REAPseq, RNA expression and protein sequencing assay; ROS, reactive oxygen species;
RRMS, relapsing–remitting multiple sclerosis; scRNAseq, single-cell RNA sequencing; smFISH, single-molecule fluorescent
in situ hybridization; SNP, single-nucleotide polymorphisms; snRNAseq, single-nucleus RNA sequencing; ST, spatial
transcriptomics; TLR, toll-like receptor; UMI, unique molecular identifier; WM, white matter; WML, white matter lesion.
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INTRODUCTION
Multiple sclerosis (MS) is a common chronic neurodegenerative
disease of the central nervous system (CNS) affecting 2.5
million people worldwide. MS symptoms include muscle
weakness and spasms, movement difficulties, optic problems,
fatigue, and acute or chronic pain (Koriem, 2016). In MS,
demyelination contributes to axonal loss and gives rise to a
neuroinflammatory environment. This provokes an immune
response involving infiltrating immune cells and CNS-resident
glial cells, including microglia, the innate immune cells
of the CNS. Under homeostatic circumstances, microglia
scan their surroundings with ramified processes and protect
the nervous system from neural damage and inflammation.
During pathology, microglia change their phenotype toward
immune-reactive microglia. Morphologically, immune-reactive
microglia acquire a more amoeboid morphology with retracted
processes and secrete proinflammatory cytokines to aim for
attenuated disease progression. A range of microglia phenotypes
have been reported, possibly with distinct molecular and
functional signatures, although these have not yet been
fully elucidated.
In MS, demyelinated areas can be classified as preactive,
active, chronic active, inactive, and remyelinated lesions,
based on the degree of inflammation, demyelination, and
axonal degeneration (Kuhlmann et al., 2017). This lesion
heterogeneity is associated with alterations in microglia
phenotype and functionality, giving rise to different microglia
subtypes. However, the exact role and functions of different
microglia subtypes in MS and other CNS diseases are
largely unresolved. In addition, under healthy conditions,
several factors contribute to microglial heterogeneity, for
example the CNS region where the microglia reside in.
Different subtypes of microglia are found in gray matter
(GM) versus white matter (WM) (Anderson et al., 2007;
McKay et al., 2007; van der Poel et al., 2019). Considerable
variation in microglia subtypes and density has been
described between brain regions as well. Lawson et al.
(1990) reported variation in the density of microglia
processes with a more than fivefold difference between
brain regions. Furthermore, density variation was even
observed within one brain region (Lawson et al., 1990),
illustrating the importance of regional analysis. Why
certain brain areas have a higher microglia density than
others is not yet understood. In addition to microglia
heterogeneity within an individual, microglia also differ
between species and between male and female individuals,
which until now mainly has been studied in mice and
humans (Lenz et al., 2013; Torres-Platas et al., 2014;
Galatro et al., 2017; Gosselin et al., 2017; Hanamsagar et al.,
2017; Guneykaya et al., 2018; Villa et al., 2018; Geirsdottir
et al., 2019). Furthermore, differences in the microglia
transcriptome are observed when comparing microglia
from various brain regions, and it has been shown that
these regions are non-uniformly affected by aging (Grabert
et al., 2016). Recently, high-resolution transcriptomic
analysis, such as single-cell and single-nucleus sequencing,
has contributed to a better understanding of microglia
heterogeneity during development, in health, and disease
(Keren-Shaul et al., 2017; Mathys et al., 2017; Brioschi
et al., 2019; Hammond et al., 2019; Schirmer et al., 2019;
Masuda et al., 2020).
Although these studies provided important insights and
identified novel microglia subtypes, spatial information of the
analyzed cells in their tissue of origin is lacking. In the past
few years, technologies for the generation of gene expression
that combine spatial information with gene expression data have
been improved. Furthermore, single-cell proteomic methods,
such as cellular indexing of transcriptomes and epitopes by
sequencing (CITE-seq), are evolving. These methods will provide
more insight into (regional) microglia heterogeneity under
healthy circumstances and in case of CNS disease. Here,
we will review recent studies in the context of MS that
have implemented such methods and discuss their respective
advantages and disadvantages.
MICROGLIA IN MS
Multiple sclerosis is a heterogeneous disease in which different
types of lesions are located in the CNS, with high variability
in the number and type of lesions not only between patients
but also within patients (Minneboo et al., 2005; Metz et al.,
2014). Disease severity correlates with a higher lesion load
(number of lesions per brain area), a higher number of
chronic active lesions, and a higher proportion of foamy
microglia/macrophages (Luchetti et al., 2018). Different
cell types are involved in MS; a continuous cross-talk
of astrocytes, oligodendrocytes, microglia, and neurons
takes place within the brain. One of the key functions of
oligodendrocytes is the production of myelin to ensheath
axons for neurotrophic support and to facilitate optimal
action potential transduction through the CNS (Kuhn et al.,
2019). However, under pathological circumstances, these
CNS cell–cell interactions are affected. Disturbances in the
homeostatic environment initially lead to the activation
of microglia, which is necessary for debris and pathogen
clearance, repair, and formation of new cells to restore
homeostasis (Peferoen et al., 2013). Also in MS, microglia
get activated and migrate to the place of injury to clear
debris, contribute to the repair of tissues/cells, and interact
with surrounding neurons and astrocytes while secreting
anti-inflammatory factors to dampen stress and promote
remyelination (Luo et al., 2017; Prinz et al., 2019; Voet
et al., 2019). However, activated microglia can also secrete
proinflammatory factors that affect neighboring cells, including
oligodendrocytes, resulting in oligodendrocyte death and
production of poor-quality myelin sheaths (Luo et al., 2017;
Masuda et al., 2020). In turn, oligodendrocytes produce
chemokines, cytokines, and chaperokines, while astrocytes
secrete proinflammatory genes, chemokines, and growth factors
to control microglia activity, phagocytosis, and migration (Jha
et al., 2019), illustrating a complex signaling network between
cells during MS pathology.
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White Matter Microglia Lose Their
Homeostatic Profile Upon
Neuroinflammation Associated With MS
Lesions
Neuroinflammation in the CNS is associated with a loss of
the homeostatic microglia profile, which has been observed
in various neuroinflammatory diseases (Dubbelaar et al.,
2018). Beaino et al. (2017) have shown that, in mice,
the local neuroinflammatory environment affects microglia
activity by downregulating the expression of the homeostatic
microglia marker P2ry12. Using human microglia in vitro, they
identified that a proinflammatory environment decreases P2RY12
expression (Beaino et al., 2017). This is supported by data that
show a decrease in the level of P2RY12 in normal-appearing
white matter (NAWM) and minimal P2RY12 immunoreactivity
in active lesions in postmortem human MS tissue (Zrzavy
et al., 2017). The same pattern of expression was seen for the
homeostatic microglia marker TMEM119 (Zrzavy et al., 2017;
Van Wageningen et al., 2019). Interestingly, P2RY12 reappeared
in mixed active–inactive white matter lesions. This study
revealed that messenger RNA (mRNA) levels of P2RY12 and
TMEM119 are regulated by interleukin-4 (IL-4) and interferon-
gamma (IFNγ). In contrast to white matter lesions (WMLs)
and NAWM, levels of P2RY12 and TMEM119 did not differ
between gray matter lesions (GMLs) and normal-appearing gray
matter (NAGM). This could be explained by the lower number
of lymphocytes observed within GMLs compared to WMLs,
as lymphocytes secrete inflammatory mediators such as IL-4
and IFNγ and thus indirectly regulate P2RY12 and TMEM119
expression (Van Wageningen et al., 2019).
Microglia in MS Lesion Pathology
Lesions are often classified by the presence/absence of certain
proteins to indicate de- or remyelination and/or inflammation.
To classify these lesions, immunohistochemistry (IHC) can be
performed using the inflammation markers human leukocyte
antigen DR isotype (HLA-DR) and/or CD68 and a myelin
marker, such as myelin proteolipid protein 1 (PLP1). Preactive
lesions can be recognized by nodules of activated microglia
(elevated levels of HLA-DR and CD68) in the absence of
demyelination (van Horssen et al., 2012). These clusters of
activated microglia express, e.g., tumor necrosis factor alpha
(TNFα) and interleukin-10 (IL-10), which both play a role
in cell survival, while IL-10 exerts also anti-inflammatory
effects and is important for neurogenesis (Zhou et al., 2009;
van Horssen et al., 2012; Pereira et al., 2015). Within these
lesions, microglia have a ramified morphology and express
the homeostatic markers P2RY12 and TMEM119, reflecting a
(partly) homeostatic state (Figure 1).
In the healthy brain, oligodendrocytes and myelin are
depositories of iron, an essential element for the regulation
of myelination and oxidative phosphorylation (Hametner
et al., 2013). However, in active MS lesions, oligodendrocytes
are vulnerable to the inflammatory environment and, when
damaged, release iron into the extracellular space, leading to the
generation of reactive oxygen species (ROS) and uptake of iron by
microglia and macrophages. Active lesions are characterized by a
demyelinated core, containing an abundance of foamy myelin-
containing microglia within the lesion. Another hallmark of
active lesions is disruption of the blood–brain barrier (BBB),
combined with leukocyte infiltration into the CNS (Kuhlmann
et al., 2017; Grajchen et al., 2018). As a consequence, reactive
microglia start synthesizing ROS, resulting in local oxidative
stress, DNA damage, and neurotoxicity (Hametner et al., 2013,
2018; Yauger et al., 2019). These iron-laden microglia have
the tendency to stay in this proinflammatory state, impairing
clearance of myelin debris, making it harder for oligodendrocytes
to migrate toward the lesion site and, as a result, complicating
remyelination processes (Mairuae et al., 2011; Lee et al., 2019).
Compared to active lesions, mixed active/inactive (chronic
active) lesions contain significantly fewer infiltrated immune
cells (Figure 1). Chronic active lesions can be recognized by
a rim of HLA-DR-positive cells surrounding the demyelinated
area. These reactive microglia contain phagocytosed iron and
other phagocytosed products such as myelin and neuronal
debris, which contribute to their amoeboid phenotype (Gillen
et al., 2018). Dal-Bianco et al. (2017) visualized these lesions
using magnetic resonance imaging (MRI) and showed that
lesions with an iron-positive microglia/macrophage rim have
a higher probability to expand than lesions with an iron-
negative rim, which often become smaller, probably due to
remyelination. This could indicate that, in lesions with iron-
positive rims, remyelination is impaired (Dal-Bianco et al., 2017).
Over time, the infiltrated immune cells disappear, resulting in a
chronic silent lesion (inactive lesion). The majority of microglia
in inactive lesions are positive for the homeostatic marker
P2RY12, but these cells also still express proinflammatory factors
(Figure 1) (Beaino et al., 2017; Zrzavy et al., 2017).
Remyelination in MS
Cells from the oligodendrocyte lineage are important for
remyelination within lesions. Remyelinated lesions show
microglia polarization from a proinflammatory state toward
an anti-inflammatory phenotype, necessary for the initiation
of remyelination (Miron et al., 2013). First, a proinflammatory
state is initiated to clear myelin debris and to stimulate
oligodendrogenesis in newly formed lesions. When lesions
expand, phagocytes acquire a more anti-inflammatory state
and produce factors (IL-4, IL13, and IL-10) required for OPC
differentiation (Butovsky et al., 2006; Miron et al., 2013; Cunha
et al., 2020). This results in the de- and remyelinated regions
that are often detected in/around active lesions. In remyelinated
lesions, the so-called shadow plaques, iron accumulation is
absent, suggesting that microglia present in these lesions have
the capacity to clear myelin debris, enabling the maturation
of OPCs, which results in the ability to remyelinate axons
(Lampron et al., 2015; Dal-Bianco et al., 2017). In support of this
notion, impeding myelin clearance through deletion of Cx3cr1,
a receptor involved in microglia–neuron crosstalk, resulted
in inefficient remyelination of axons (Lampron et al., 2015).
Overall, microglia are very dynamic, and the environmental
heterogeneity between and within MS lesions is associated
with different microglia responses. Moreover, iron-positive
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FIGURE 1 | Illustrative overview of different human WM lesion types. Preactive lesions express the homeostatic microglia markers P2RY12 and TMEM119, while
expression of these markers is minimal/absent in active lesions and reappears in chronic active lesions and inactive lesions; for remyelinated lesions, the expression
of these genes remains unidentified. In each lesion type, CD68+ cells are represented, either within the lesion or at the rim of the lesion. The rim of chronic active
lesions can either contain iron-positive microglia/macrophages resulting in a higher probability for lesion expansion or iron-negative microglia/macrophages, which
often results in smaller lesions over time.
microglia/macrophages that form a rim around the lesion could
impair the remyelination process, resulting in slowly expanding
lesions rather than shrinkage of the lesion.
HETEROGENEITY OF MICROGLIA IN
THE CNS
For a long time, research focused on WM pathology, as it was
considered the main pathological characteristic of MS. However,
demyelination and lesion formation is not restricted to the WM
and also occurs in the GM (Petiet et al., 2016). In the last
decades, studies expanded to include the GM due to advances
in visualization technologies and IHC. Similar to WM lesions,
cortical GM lesions can be subdivided into different lesion
types: leukocortical (lesions that extend in subcortical WM),
intracortical (lesions that do not extend to subcortical WM or the
surface of the brain), and subpial lesions (lesions that extend to
the surface of the brain). It has been shown that WM lesion load
is related to cortical lesions; leukocortical and intracortical lesions
correlated with the incidence of chronic active lesions, reactive
site load, and the proportion of remyelinated lesions. However,
no correlation was detected between WM lesion load and subpial
lesions, indicating that subpial lesion formation is initiated
by different underlying processes than in leukocortical and
intracortical lesions (Luchetti et al., 2018). Interestingly, subpial
lesion formation is often located close to sites of meningeal
inflammation, which might contribute to GM lesion pathology
(Howell et al., 2011). Moreover, differences in microglial
phenotype, as well as transcriptomic differences, have been
observed between species and male and female. Here, we focus
on WM/GM microglial heterogeneity and microglial differences
between species and sex (summarized in Figure 2).
Microglia Are Heterogenous Across
Brain Regions and Differ in WM
Compared to GM Tissue
Microglia are present in both the WM and GM; however, these
microglia are phenotypically different. Previous studies reported
that microglia differ in density, morphology, and transcriptomic
signature throughout the CNS, which could contribute to the
difference in lesion pathology observed in WM versus GM
(Lawson et al., 1990; Savchenko et al., 1997; Mittelbronn et al.,
2001; de Haas et al., 2008; Böttcher et al., 2019; van der
Poel et al., 2019; Van Wageningen et al., 2019). Furthermore,
it has been observed that microglia show a region-specific
gene expression profile; GM microglia were enriched for genes
involved in type-I IFN responses, while WM microglia expressed
high levels of genes involved in the nuclear factor kappa B
(Nf-κb) pathway (van der Poel et al., 2019). Transcriptional
differences were also observed in NAWM compared to NAGM;
NAWM microglia increased the coexpression of genes involved
in glycolysis and metal ion homeostasis (ABCB6, CCR2, LPAR6,
SDC1, and SLC25A37), whereas in NAGM, microglia increased
the coexpression of genes associated with lysosomal pathway,
lipid catabolism, and foam cell differentiation (ASAH1, CTSD,
SCARB2, ABHD2, and LPL).
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FIGURE 2 | Schematic overview of microglial heterogeneity (A) in WM versus GM regions, (B) between human and mouse male and female microglia, and (C)
between species. (A) Microglia in WM are more numerous compared to GM. Microglial activation is observed in NAWM, while in GM, microglial activation is
conserved to specific areas. (B) Under homeostatic conditions, mouse male microglia have a higher process volume, process area, number of branches, and
number of intersections compared to female microglia. These male microglia appeared to be delayed in the transcriptional development compared to female
microglia and show increased expression of Mhc-I and Mhc-II. LPS treatment decreased male microglial total process volume and area, whereas in female individual,
no significant effect of LPS on microglia morphology was observed. In response to LPS, male microglia increased their transcriptional development to a level that
was comparable to the transcriptional development in female microglia observed prior to the LPS challenge and increased expression of immune response genes,
while female microglia increased the expression of cell motility genes. In opposite, homeostatic human male microglia have an accelerated transcriptional
development in comparison to female microglia. (C) Spi1, Irf8, Csf1r, and Tgfbr2 are core microglial genes that are conserved during evolution, since these genes
were strongly expressed in human, macaque, marmoset, sheep, mouse, and hamster. Human microglia subcluster into different microglial types, while mouse,
macaque, marmoset, hamster, and sheep microglia grouped mainly into one microglia type, based on their gene expression profiles.
Generally, microglia are more numerous in human WM
than in GM (Figure 2) (Mittelbronn et al., 2001), which is in
contrast to mice, where microglia numbers are higher in the
GM (Kondo and Duncan, 2009; Lawson et al., 1990). However,
microglia density is not homogeneous between specific WM
and GM regions. In mice, the highest microglial density was
detected in the frontal cortex, olfactory bulb, basal ganglia, and
substantia nigra (regions low in myelin), while intermediate
microglial density was detected in the cerebral cortex, thalamus,
and hypothalamus, and microglial density was the lowest in
the brainstem, cerebellum, and fiber tracts (myelin-rich regions)
(Lawson et al., 1990). To determine whether microglia from
WM or GM respond differently to the same lesion type, Cǎtǎlin
et al. (2013) induced local tissue damage in both the WM
(spine) and GM (cortex) with high-power laser pulses. The
morphological response of WM and GM microglia did not differ
upon this damaging cue. Although no difference in microglia
morphology was identified, the speed at which microglia
processes extended toward the lesion site (µm/min) was faster
in WM compared to GM (Cǎtǎlin et al., 2013). Furthermore,
Verdonk et al. (2016) used a Cx3cr1:GFP/++ model (mice in
which the Cx3cr1 promoter drives expression of a GFP reporter
gene) and treated one group with lipopolysaccharide (LPS).
Twenty-four hours after LPS treatment, Verdonk et al. (2016)
observed morphological differences in brain-derived microglia
between the two groups; the cell body and cytoplasm area were
significantly larger in microglia from the LPS group compared
to controls. Interestingly, in both the LPS and control group,
the cytoplasm area was significantly larger in the cerebellum
compared to frontal cortex, hippocampus, and striatum. No
significant differences were observed in cytoplasm area between
these last three brain regions (Verdonk et al., 2016). Summarized,
microglia are not uniformly distributed throughout the WM and
GM brain regions. Microglia change their phenotype in response
to immunomodulatory stimuli; however, differences are observed
between brain regions.
Regional Differences in a Cuprizone Mouse Model
Cuprizone mouse models are frequently used to study de- and
remyelination in WM and, to a lesser extent, in GM. Cuprizone is
a toxic compound that induces oligodendrocyte death, resulting
in robust demyelination. Mice on a cuprizone diet for a limited
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time are used as a model to resemble de- and remyelination in
MS. Extensive demyelination occurs within the corpus callosum
(CC); however, also GM areas such as the cortex are affected by
demyelination (Skripuletz et al., 2008). A previous study from
Gudi et al. (2009) showed that microglia start to accumulate in
the CC 3 weeks after the start of the cuprizone diet and reach their
peak at 4.5 weeks of treatment. In addition, a significant increase
in the number of activated microglia was identified within
the cortex; however, the increase was much lower compared
to microglia accumulation within the CC (Gudi et al., 2009).
Interestingly, heterogeneity in microglial distribution throughout
the cortex was observed; at 3 weeks of cuprizone treatment,
microglia mostly resided in cortical layer V, while at 4–4.5 weeks
of treatment, microglia were equally distributed through both
cortical layers V and VI. At weeks 5–5.5, the highest microglia
number was observed in cortical layer VI, while at all these
timepoints, demyelination was present in all cortical layers.
Oligodendrocytes were also higher in number in these two layers
of the cortex 4.5 weeks after the start of the cuprizone diet
(Gudi et al., 2009). Cortical layers V and VI are most densely
myelinated and are in proximity to the CC, which is one of the
regions most affected by demyelination induced by cuprizone,
possibly explaining the increase in microglia in these GM regions
(Gudi et al., 2009; Tomassy et al., 2014). Another observation
was increased microglial proliferation in both the CC and
cortex during the demyelination phase. However, the number
of proliferating cells decreased again during remyelination in
both the WM and GM (Gudi et al., 2009). In MS lesions,
remyelination is more extensive in the GM than in the WM, and
the remyelination process occurs at a higher speed, which could
be due to the higher number of OPCs present in GM lesions
compared to WM lesions (Chang et al., 2012). Most cuprizone
studies include young mice that receive a cuprizone diet for
5 weeks to investigate remyelination. In aged mice (6 months
of age), 5 weeks cuprizone treatment did not result in complete
demyelination; however, complete demyelination was achieved
following 6.5 weeks of cuprizone treatment (0.4% cuprizone)
with high accumulation of microglia within the CC. Interestingly,
these mice showed incomplete remyelination, with increased
numbers of microglia and prolonged microglial activation in the
CC, even 3.5 weeks after withdrawal of cuprizone, which could
suggest that aged microglia are less capable of phagocytosing
debris, resulting in the delayed and incomplete remyelination
seen in aged cuprizone mice (Gingele et al., 2020). Thus, when
studying MS pathology, the use of an aged cuprizone mouse
model should be considered, as this offers more reliable insights
in de- and remyelination processes than the young cuprizone
mouse model that is most commonly used.
Microglia Differences Between Species
To study MS, cuprizone and EAE mouse models are commonly
applied (Torkildsen et al., 2008; Constantinescu et al., 2011).
However, animal models do not fully approximate or recapitulate
human disease and pathology. First of all, when comparing
mice to humans, we should take into account that the
environment laboratory mice reside in is clean and controlled,
while for humans, the environment changes frequently and
contains microbes that could cause infections. Furthermore,
genetic variation and environmental factors contribute to donor
variation, while mice are generally inbred and most factors are
held constant throughout an experiment. Here, we will discuss
the differences in microglia phenotype and transcriptomic
signature between species, with a focus on mice and humans.
Gosselin et al. (2017) compared mouse and human microglial
transcriptomic data. Mice and humans showed an extensive
overlap in microglial gene expression patterns (Pearson’s
r = 0.806), although, genes involved in the regulation of
the complement system and brain structure development
were expressed at a higher level by human microglia
(Gosselin et al., 2017).
Recently, a microglial gene expression profiling study of eight
species across evolution—human, macaque, marmoset, sheep,
mouse, hamster, chicken, and zebrafish—using a combined
single-cell and bulk sequencing approach, was reported
(Geirsdottir et al., 2019). Since chicken and zebrafish microglia
showed evolutionary distance to the other six species, these
two species were excluded from further analysis allowing
the characterization of subtle microglial changes between
mammalian species. Hierarchical clustering showed that the
macaque transcriptomic signature was most similar to the human
transcriptomic signature. Interestingly, all six species abundantly
expressed SPI1, IRF8, CSF1R, and TGFBR2, genes with a critical
role in microglial development, suggesting that these genes
are core microglial genes that are conserved during evolution
(Figure 2). In total, 163 genes were detected that were both
conserved and specific for microglia. Moreover, it was observed
that human microglia subcluster into different microglia types,
based on their gene expression profiles, while mouse, macaque,
marmoset, hamster, and sheep microglia grouped mainly into
one type (Figure 2). One such human microglial subtype was
identified by high expression of inflammatory genes, which could
be a result of the effect of aging (Geirsdottir et al., 2019).
Our group previously reported that natural aging affects
microglia differently in mice and humans. Just a small number
of gene expression changes induced by aging are shared between
mice and human microglia, and quite a few genes show opposite
expression patterns (Galatro et al., 2017). Of note, although
microglia age differently under healthy conditions, upon damage
or disease, mouse and human microglia show very similar
responses (Holtman et al., 2015b). The aging-related differences
in expression patterns might be the result of external (signaling)
factors, but also intrinsically, microglia could be dictated to
express different genes upon aging. One of the processes possibly
affecting microglia aging is their turnover rate. The microglia
population is locally maintained by self-renewal. In adult rodents,
it is unequal throughout the CNS and appeared to be higher in
the dentate gyrus, where microglial proliferation declines faster
with age compared to other brain regions. This could lead to
an earlier-reached state of microglial senescence in this brain
region, as a result of the Hayflick limit, which describes that cells
have a finite capacity to divide due to telomere shortening; most
cells divide around 40–60 times (Hayflick, 1965; Askew et al.,
2017). This could explain the significant decrease in microglial
proliferation rate that was observed in the dentate gyrus during
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aging. In humans, microglial proliferation rate has been estimated
to be 2.9× higher compared to rodents (Askew et al., 2017).
Furthermore, humans have a much longer lifespan than mice.
When studying age-related brain diseases, it is important to
take these differences into account, as they might influence the
translational value from studies in mice to the human situation.
Microglial Sex Differences
Women are at a two to three times higher risk to develop MS
and suffer from more frequent relapses than men (Tremlett
et al., 2008; Sellner et al., 2011). It was observed that MS
characteristics are, among others, related to sex differences
(Ribbons et al., 2015; Luchetti et al., 2018). In relapsing–remitting
MS (RRMS), male individuals progress significantly faster than
female individuals (Ribbons et al., 2015). In male individuals, a
higher incidence of chronic active lesions was observed compared
to female individuals. In addition, cortical lesions occurred
more frequently in male than in female individuals. However,
a direct relationship was observed between the presence of
cortical lesions and disease severity in female individuals, while,
interestingly, no such relation was observed in male individuals.
Another observation was that the presence of chronic active
lesions positively correlated with disease severity and lesion
load (Luchetti et al., 2018), which could explain why in RRMS
patients, a faster progression is observed in male compared to
female patients.
So far, most research has focused on sex differences in T-cell
immune responses in MS (Kodama and Gan, 2019). However,
sex-specific differences have also been described for microglia.
During embryonic and early postnatal development, mouse
male and female microglia develop in a similar way based on
gene transcription analysis (Hanamsagar et al., 2017). Microglia
transcriptionally and morphologically reach a mature state at
postnatal day 14, where they resemble homeostatic microglia
from adult mice (Bennett et al., 2016; Matcovitch-Natan et al.,
2016). However, in adult mice, it was observed that the increase
in developmentally regulated genes during normal development
is delayed in male microglia compared to female microglia,
which can be used as an indicator for developmental maturation
(Hanamsagar et al., 2017). When early adult mice were injected
with LPS 2 h prior to isolation, changes in morphology, as well
as at the transcriptional level, were observed in microglia. LPS
treatment decreased male microglial total process volume and
area, which was inversely correlated with gene expression changes
normally associated with microglial developmental maturity. In
female individuals, no significant effect of LPS on microglial total
process volume and area was observed (Figure 2) (Hanamsagar
et al., 2017). In addition, sex-specific gene expression responses
were identified; male microglia adapted their expression of
developmentally regulated genes to a level that was comparable to
the expression of these genes in female microglia observed prior
to the LPS challenge. LPS treatment increased the expression
of immune response genes in male microglia, while in female
microglia, cell motility genes were highly expressed (Figure 2).
Female mice go through cyclic hormonal changes; however,
different phases of the estrous cycle did not result in altered gene
expression in microglia (Hanamsagar et al., 2017).
Interestingly, in humans, male microglia have an accelerated
transcriptional development compared to female microglia
(Figure 2) (Hanamsagar et al., 2017). Hanamsagar et al. (2017)
hypothesized that this mouse–human difference could be a
result of the relatively sterile environment that mice reside
in. They postulated that males could be more susceptible to
infectious agents during development than females, stimulating
the transcriptomic development (Hanamsagar et al., 2017).
Morphological differences were observed when comparing
microglia in early adult male and female mice (Lenz et al.,
2013; Hanamsagar et al., 2017; Guneykaya et al., 2018; Villa
et al., 2018). Differences in microglial process volume, process
area, number of branches, and number of intersections were
observed, which were all increased in males compared to
females (Figure 2) (Hanamsagar et al., 2017). Guneykaya et al.
(2018) also describe an increase in microglial density in the
cortex, hippocampus, and amygdala in 13-week-old male mice.
Furthermore, an increase in microglial soma size was seen in
these three brain areas in adult male mice. These findings suggest
that male microglia are in a more primed state and are prepared
to directly react to immunomodulatory stimuli. This is supported
by a higher expression of proteins involved in toll-like receptor
(TLR) pathways found in male microglia, as determined by
mass spectrometry-based proteomics (Guneykaya et al., 2018).
In addition, NF-κB transcription activity was 2.4-fold higher in
adult male microglia, also indicating a higher responsiveness to
immunological stimuli (Villa et al., 2018). Thereby, adult male
microglia have a higher antigen-presenting potential than adult
female microglia. Using flow cytometry analysis, male microglia
showed higher expression of Mhc-I in the hippocampus and
amygdala, whereas Mhc-II expression was increased in the cortex,
compared to the expression of Mhc-I and Mhc-II in female
microglia (Guneykaya et al., 2018).
The different functional properties and the lower
transcriptomic developmental state of human female microglia
could be one of the factors contributing to the higher risk of
MS in female individuals. In the last years, research groups have
studied sex-specific features of microglia and their response
to immunomodulatory stimuli. However, less is known about
the effect of sex differences in microglia in disease and if these
differences contribute to the development and progression of
neurodegenerative diseases, such as MS.
Analysis of Neuroinflammation in the
Brain
In addition to the differences observed in microglial morphology
in WM and GM, microglia change their phenotype during
neuroinflammation. One method to analyze neuroinflammation
is translocator protein (TSPO) positron emission tomography
(PET) imaging. TSPO is present at the mitochondrial
membrane, with increased expression in reactive astrocytes
and proinflammatory microglia/macrophages (Chechneva and
Deng, 2016; Beckers et al., 2018; Singhal et al., 2019). Under
normal conditions, TSPO is expressed only at low levels in
the GM in humans (Vowinckel et al., 1997; Banati, 2002).
Using experimental-autoimmune encephalomyelitis (EAE), a
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mouse model for MS, Vowinckel et al. (1997) showed high
concentrations of TSPO in the inflamed WM of EAE mice. In
MS patients, significant differences in the uptake of a radioligand
for TSPO were identified in specific regions of cortical GM
areas compared to healthy controls; a recent study by Singhal
et al. (2019) detected an increase in radioligand uptake in the
hippocampus, amygdala, posterior cingulate, midcingulate,
and rolandic operculum, indicating higher levels of microglial
activation in these GM areas compared to healthy controls
(Figure 2). However, microglia activation in total cortical GM
did not differ from healthy controls (Singhal et al., 2019).
A similar approach was used by Datta et al. (2017). Datta
et al. (2017) detected that radioligand uptake predominantly
occurred in the thalamus and that MS patients showed higher
radioligand binding to TSPO in this region than healthy
controls. Furthermore, an increase in radioligand uptake was
identified in NAWM, compared to healthy WM (Datta et al.,
2017), which is supported by Van Wageningen et al. (2019)
who observed a decrease in the homeostatic gene expression of
P2RY12 and TMEM119 in microglia, suggesting a shift toward
reactive microglia.
All things considered, it is important to keep in mind
that microglia are heterogenous in both WM and GM areas.
Throughout the CNS, microglia show differences in density,
morphology, and transcriptomic signature, with the latter being
described more in detail in Chapter “Transcriptomic Profiling,
an Initial Step Toward Understanding MS Heterogeneity.” In
MS, higher levels of microglia activation can be found in a
number of specific GM areas, while microglia activation levels
are more or less homogeneous throughout the WM. Based on
their gene expression profile, these human microglia subcluster
into different microglial types, while in other species, microglia
subcluster into only one microglial type. Moreover, male human
microglia appeared to be more mature than female microglia,
while interestingly, this is the other way around in mice. These
male mice microglia have a more primed phenotype and a
higher antigen-presenting potential than female mice microglia,
and when responding to immunomodulatory stimuli, they push
their transcriptomic signature to a more mature state. However,
the question why some brain areas show higher microglial
density and/or morphology compared to other brain areas still





of Human MS Tissue
Transcriptomic profiling of human MS postmortem brain
tissues initially was performed using microarrays and bulk RNA
sequencing approaches, which mainly resulted in information
about neuronal cells, simply because neurons are more abundant
than glial cells (Zheng et al., 2018). Therefore, combinations
with laser capture microdissection (LCM), fluorescent-activated
cell sorting (FACS), and region-specific analysis were applied
to decrease sample heterogeneity. These studies identified gene
signatures of active lesions (immune-related genes), which differ
from the inactive lesion signature (apoptosis, stress-related
genes) (Mycko et al., 2004; Elkjaer et al., 2019). An LCM-
microarray study of chronic MS lesions detected increased
expression of genes encoding for heat-shock proteins (HSP) in
a region-dependent manner. Differences in specific HSP gene
expression were observed between the margin and the center
of the lesions, compared to NAWM. This lesion margin and
center heterogeneity is potentially regulated by heat shock factor
four (HSF4) (Mycko et al., 2012). In addition, inactive lesions
increased expression of genes related to extracellular matrix
components and steroid metabolism, while the rim of active
lesions expressed genes related to lipid metabolism and lysosome
signaling, including genes encoding for scavenger receptors
(OLR1, CD68, MSR1, CXCL16), which are potential mediators of
early demyelination (Figure 3) (Hendrickx et al., 2017). The role
of lipid metabolism in early MS pathogenesis has been further
elucidated, where lipid metabolism-related genes (LPL, EEPD1,
CHI3L1) were enriched in NAWM compared to CWM (van der
Poel et al., 2019). Besides lesion-specific profiles, a region-specific
gene signature of the choroid plexus was identified, characterized
by increased expression of hypoxia-related, neuroprotective,
and secretory genes (Rodríguez-Lorenzo et al., 2020). Taken
together, high molecular complexity is detected between lesion
types, where the immune system and lipid metabolism are
major processes linked with active lesions and apoptosis, while
stress response and extracellular matrix changes are related to
inactive lesions.
High-Resolution Transcriptomic Profiling
Bulk transcriptomic profiling contributed to MS research,
although its resolution by the analysis of pools of cells, masking
cellular heterogeneity. Currently, a broad spectrum of sequencing
technologies is available to analyze single cells (scRNAseq,
see Figure 3 for an overview). Two types of amplification
strategies can be distinguished: protocols that measure full-length
complementary DNA (cDNA) molecules (SMART-seq2) (Picelli
et al., 2014) and protocols that measure the 3′ or 5′ end of
cDNA molecules linked to a unique molecular identifier (UMI)
(MARS-seq, STRT, CEL-seq2, Dropseq, and inDrops). The use of
UMIs massively increase the throughput; however, it decreases
sensitivity, which remains higher in sequencing full-length
cDNA. Combinations with microfluidics and droplet-based
sequencing platforms (Fluidigm C1, Chromium-10X genomics
and Indrop-Cellbio) created easy-to-use library preparation
protocols. The advantages and disadvantages of these protocols
are reviewed by See et al. (2018). For human CNS tissue, it is
logistically challenging to obtain a viable single-cell population
from fresh tissue prior to sequencing; therefore, some alternatives
can be considered. If a sufficient number of cells can be obtained,
possibilities exist to use a fixation buffer such as methanol,
allowing temporal storage of single-cell suspensions at −80◦.
However, not all cells will recover from this process, and it
should be tested if these buffers are suitable for glia cells
(Chen et al., 2018; Böttcher et al., 2019). Instead of analyzing
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FIGURE 3 | Illustration depicts various methodologies to detect microglia heterogeneity, (A) distinguished in transcriptomics, (B) in situ spatial detection, (C)
proteomics, and (D) ex situ spatial detection. (A) After tissue dissociation and often FACS analysis, a library can be prepared to detect microglia heterogeneity.
Sequencing detects heterogeneity at high (single cell/nucleus) resolution, but sensitivity is low, compared to microarray, bulk-seq, and qPCR. Several studies already
detected homeostatic and MS-associated microglia clusters, characterized by the genes depicted in the blue and red squares, respectively. (B) The golden standard
methods using a single probe (smFISH) and a probe with amplifiers (RNAscope) are followed by high-throughput in situ detection of genes, via multiple rounds of
probe hybridization, cleavage, imaging, and finally sequence decoding. (C) Standardly applied proteomic methods use antibodies containing fluorophores to detect
a protein, while high-throughput proteomics methodologies make use of antibodies labeled with heavy metals (mass cytometry) or DNA barcodes
(REAP-seq/CITE-seq). REAP-seq and CITE-seq antibodies also contain an RNA binding site for simultaneous RNA detection. (D) A tissue section is placed on a
barcoded slide with beads (slide-seq) or spots (spatial transcriptomics), which allows to explore regional gene expression in MS lesions.
cells, individual nuclei isolated from fresh or frozen tissue can
be profiled, a technique referred to as single nucleus RNA
sequencing (snRNAseq) (Krishnaswami et al., 2016). The nuclear
transcriptome of microglia has been reported to reflect the
cellular transcriptome under homeostatic conditions and also
following an LPS challenge (Gerrits et al., 2020).
Microglia Subtypes
Recently, high-resolution transcriptomic profiling (Figure 3)
confirmed the existence of molecularly distinct microglia
subtypes, with potentially specific functionalities (Keren-Shaul
et al., 2017; Mathys et al., 2017; Geirsdottir et al., 2019;
Hammond et al., 2019; Jordǎo et al., 2019; Masuda et al.,
2019; Schirmer et al., 2019). To date, dynamics of microglial
subtypes have been studied under homeostasis and during
development, aging, and various neurodegenerative disease
conditions in human and mouse models [including cuprizone
and EAE, (de)(re)myelination and inflammation model for MS,
respectively] (reviewed by Masuda et al., 2020). Complexity
in microglial subtypes is increased in disease compared to
homeostatic conditions and is highly influenced by the brain
microenvironment. The availability of an extensive amount of
transcriptomic profiles facilitated the separation of microglia
from CNS-associated and blood-derived macrophages in gene
expression datasets, based on marker genes (Jordǎo et al.,
2019). scRNAseq/snRNAseq studies of microglia derived from
human postmortem brain tissue from MS donors are scarce
and only available with a limited number of donors and
cells. However, CNS single-cell data are highly relevant for
understanding MS pathogenesis. Masuda et al. were first to
sequence individual CD45-positive cells isolated from MS brain
tissue. Within their dataset, clustering analysis of 1,180 control
microglia and 422 MS microglia identified 7 distinct clusters,
all characterized by expression of TMEM119 and P2RY12,
referred to as microglia core genes. Controls mainly consisted
of three clusters with high expression of microglia core genes
linked to homeostatic functions. Homeostatic cluster four was
present in controls and MS; this cluster decreased microglia core
genes and increased cytokine and chemokine gene expression,
referred to as preactivated microglia. In MS, three clusters
were more abundant. The first cluster had increased expression
of CTSD, APOC1, GPNMB, ANXA2, and LGALS1, while the
second cluster was enriched for HLA genes related to antigen
presentation, and the third cluster expressed genes that could
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be involved in demyelination: SPP1, PADI2, and LPL (Masuda
et al., 2019). Recently, the first single-nuclei sequencing study
in MS has been performed. In total, 1,524 MS microglia nuclei
were compared to 159 control microglia nuclei. Hierarchical
clustering distinguished microglia with homeostatic (P2RY12,
RUNX1, CSF1R), MS-specific (activation markers, complement
factors, MHC-II and lipid genes: ASAH1, ACSL1, DPYD), and
phagocytosis- and oligodendrocytes-associated genes (CD163,
PLP1, MBP, and ST18) (Schirmer et al., 2019). These studies
indicate that unique gene expression changes occur in MS
in specialized microglial subtypes. It is still unclear which
factors initiate these gene expression changes and what is
the exact functional role of these subtypes in MS. However,
these studies provide us with candidate genes to be studied in
more detail with functional assays, which likely contributes to
future understanding of MS pathology. Taken together, high-
resolution transcriptomic studies revealed microglia landscapes,
showing the complexity of subtypes in a spatial and temporal
manner. Extended information about transcriptional profiling of
astrocytes, oligodendrocytes, and neurons in MS is available in
Box 1.
SPATIAL DETECTION COULD PROVIDE
NEW INSIGHTS IN REGIONAL
HETEROGENEITY
High-resolution transcriptomics technologies have made it
possible to study the entire transcriptome at the level of
an individual cell. These methods are highly relevant for
understanding MS pathogenesis, as they can detect differentially
expressed genes in the affected tissue and potentially identify
novel cell subtypes. However, these technologies require
disruption of the tissue for the isolation of cells or nuclei from
the tissue, and as a consequence, spatial context is lost. However,
spatial context is important in understanding cell functioning in
health and during pathology. Thus, techniques that allow spatial
detection could provide added value when studying (regional)
heterogeneity to further elucidate pathogenic features (Figure 3).
In situ Hybridization Assays
In 1969, in situ hybridization (ISH) was pioneered by Pardue
et al., and this was followed by the invention of fluorescent
probes around 10 years later (Pardue and Gall, 1969; Rudkin
and Stollar, 1977). (Fluorescence) in situ hybridization [(F)ISH]
is a technique that uses labeled DNA or RNA probes to target
a specific DNA or RNA sequence within a histological section,
thus indicating gene expression at a spatial level. A problem that
arose with this technique was that single molecules could only
be detected in regions with a low background signal. In 1998,
single-molecule FISH (smFISH) was developed by Femino et al.
(1998). smFISH includes probes labeled with five fluorochromes
that target multiple regions of the transcript, resulting in a
higher fluorescence signal, allowing specific detection of single
molecules (Femino et al., 1998). However, the use of probes
consisting of five different fluorochromes was associated with
a high risk of both false-positive and false-negative outcomes.
Furthermore, these heavily labeled probes were difficult to
develop (Femino et al., 1998; Asp et al., 2020). Raj et al.
(2008) optimized smFISH. The technique uses 40 probes, each
coupled to a single fluorochrome, resulting in more accurate
mRNA counts (Raj et al., 2008). Hammond et al. (2019) studied
microglial RNA expression patterns in mice during development,
in old age, and after brain injury. Following demyelination
injury by lysolecithin (LPC) injection, this research group used
smFISH to determine the organization of microglia within these
demyelinated lesions. Three probes were used for smFISH to label
the microglial marker Fcrls and chemokines Ccl4 and Cxcl10.
smFISH confirmed an increase in Fc receptor-like molecules+
(Fcrls+) microglia and showed higher Apoe expression after
LPC injection compared to control mice. Furthermore, smFISH
identified a spatial distribution of Ccl4 and Cxcl10 within the
lesion; both chemokines were expressed only in small specific
parts of the demyelinated area, and in most of the cases, the
chemokine expression colocalized with Fcrls+ microglia. In
human MS active lesions, also an increase in CCL4 expression
was observed, mostly in TMEM119+ microglia (Figure 3)
(Hammond et al., 2019). Another study investigated regional
GM heterogeneity by studying neuronal gene expression in the
different layers of the cortex, to further elucidate MS pathology
(Schirmer et al., 2019). Using smFISH, probes for simultaneous
detection of two to three genes of interest were included, and gene
expression was measured in cortical GM, adjacent subcortical
WM lesion areas, and controls. smFISH showed a decrease
in upper-layer neuronal marker CUX2 in completely and
incompletely demyelinated cortical MS lesions, while expression
of the interneuronal marker VIP was maintained. Furthermore,
smFISH confirmed the increase in the neuronal cell stress
markers PPIA and NORAD, which were mainly upregulated in
demyelinated cortical MS lesions (Schirmer et al., 2019). A similar
approach to smFISH is RNAscope. RNAscope uses target-specific
double Z probes that target the mRNA. Then, amplifiers and
different labels (chromogenic or fluorescent) can be added to
these Z probes. Targeted mRNA transcripts are detected as dots,
each dot representing a single copy of the mRNA. Compared to
smFISH, RNAscope probes amplify signals while simultaneously
suppressing the background noise (Wang et al., 2012).
In (sm)FISH, the number of fluorescent probes is generally
limited to three due to limitations of fluorescent microscopy,
such as the use of band- and long-pass filters (Lukumbuzya
et al., 2019). Multiplexed error-robust FISH (MERFISH), a
technique that was developed in 2015 allows for the detection of
multiple probes. MERFISH uses multiple rounds of hybridization
and imaging, with a different probe for each RNA molecule
(Figure 3) (Chen et al., 2015). These probes label the RNA
with a specific combination of readout sequences, resulting in
“barcodes” assigned to the RNAs of interest. The barcodes are
then read out by the use of fluorescent probes that target the
RNA sequences. The higher the number of rounds, the higher
the copy number of genes that can be measured simultaneously.
To adjust for detection errors that exponentially increase with
the number of rounds, error-robust encoding schemes were
added that detect and correct errors to improve accuracy and
sensitivity (Chen et al., 2015; Strell et al., 2019). A recent study
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BOX 1 | MS-associated cell subtypes.
Besides microglia, transcriptional profiling of other CNS cell types may contribute to understanding MS pathogenesis. Microglia interact with oligodendrocytes
(Peferoen et al., 2013), astrocytes (Wheeler et al., 2020; Vainchtein and Molofsky, 2020), and neurons (Pósfai et al., 2019). In addition, in these cell types,
transcriptional changes have been observed in human MS tissues. First of all, reactive GFAP-positive astrocytes are already transcriptionally distinct in MS NAWM
tissue compared to controls. In MS NAWM, astrocytes are involved in responses to iron, oxidative stress, and immune responses, and they secrete factors for
neuronal survival (Waller et al., 2016). Importantly, all above cell types are involved in (de)(re)myelination and immune signaling, which are the main processes that are
altered in MS (Domingues et al., 2016; Molina-Gonzalez and Miron, 2019). In addition, recruitment of peripheral immune cells during MS pathogenesis is mediated
by oligodendrocyte apoptosis and microglia immune activation (Chrzanowski et al., 2019). Therefore, high-resolution transcriptomic profiling of all cell types
potentially involved in MS are relevant to understand MS pathology. Oligodendrocyte lineage cells are the actual suppliers of myelin, which was for a long term
described as their only function as a pool of cells. However, high-resolution transcriptomics changed this passive view into a dynamic view, where oligodendrocyte
lineage cells display heterogeneity across brain regions (Marques et al., 2016), throughout development (Perlman et al., 2020) and during the course of MS
pathology (Jäkel et al., 2019; Schirmer et al., 2019; Yeung et al., 2019). As an example, Yeung et al. (2019) identified subsets of disease-specific oligodendrocyte
lineage cells in EAE mice. One EAE-associated subtype was characterized by increased expression of Mhc-II and interferon-responsive genes, suggesting an active
immune-modulatory role (Yeung et al., 2019). Functionally, they proved in vitro that Mhc-II-positive oligodendrocyte lineage cells performed phagocytosis (Yeung
et al., 2019). Brain tissues from MS donors also contained MHC-II-positive oligodendrocyte lineage cells, and therefore, phagocytosis by these cells is likely involved
in MS pathology. Others investigated human subcortical MS lesions, wherein a myelinating oligodendrocyte subtype increased the expression of genes associated
with cellular stress (HSP90AA1, FAIM2, ATF4, and UBB), while myelin gene expression was reduced (BCAS1, SGMS1, KCNJ10, SEMA6A, and GLDN) (Schirmer
et al., 2019). snRNAseq of various WM lesions derived from five MS donors generated a transcriptomic landscape consisting of six human oligodendrocytes
subtypes. The frequency of each subtype differed within MS lesions and compared to control WM (Jäkel et al., 2019). In a similar approach that focused on
astrocytes in EAE, astrocyte heterogeneity was detected and an EAE-associated astrocyte subtype, driven by increased Mafg and reduced Nrf2 expression, was
defined. This subtype was also present in 60% of the examined transcriptomic profiles of MS donors. In addition, immunohistochemistry showed that MAFG protein
expression was increased in active human MS lesions, while NRF2 proteins already decreased in NAWM compared to controls. MAFG decreases the expression of
NRF2, which is a negative regulator of inflammation and oxidative stress. Thus, when less NRF2 is available, inflammation is no longer inhibited. MAFG interacts with
MAT2α to block anti-inflammatory pathways. Therefore, inflammatory responses increase due to this specific astrocyte subtype (Wheeler et al., 2020). In human
tissue, isolation of astrocytes is technically challenging and, so far, has not resulted in the isolation of intact cells; therefore, analysis of astrocyte nuclei derived from
frozen MS tissues is a major improvement. Nuclei sequencing resulted in a nuclear profile specific to subcortical WM (SLC1A2) and cortical GM (CD44) astrocytes,
where all astrocyte populations expressed the marker RFX4. In the rim of active MS lesions, an increase in reactive astrocyte genes was observed (BCL6, FOS,
EDNRB, LINC01088) (Schirmer et al., 2019). Schirmer et al. (2019) sequenced single nuclei of all CNS cell types, but their population consisted mainly of neurons.
CUX2 expressing upper-layer excitatory projection neurons (EN-L2-3A/B) showed major gene expression differences between MS and control donors and trajectory
analysis defined a link with chronic inactive lesions. Functionally, CUX2-positive neurons were annotated with gene ontology (GO) terms related to oxidative stress,
mitochondrial dysfunction, and cell death. Therefore, CUX2-positive neurons are sensitive to cell damage, and especially, this neuronal subtype is reduced in MS
compared to other, preserved neuronal subtypes (Schirmer et al., 2019).
investigated the role of astrocyte heterogeneity and regulation
in MS (Wheeler et al., 2020). This group identified an astrocyte
population characterized by an increase in MAFG expression
and a decrease in NRF2 expression in EAE and MS. In addition,
MERFISH revealed that these Mafg+ astrocytes were in close
proximity to granulocyte-macrophage colony-stimulating factor
Gm-csf+ T cells (Wheeler et al., 2020). Thus, MERFISH adds
value when spatially investigating the (co-) expression of a high
number of RNAs of interest simultaneously.
Spatial in situ Sequencing Techniques
Fluorescent in situ sequencing (FISSEQ) is a method that was
first described by Mitra et al. (2003). First of all, a library with
molecules of linear DNA is generated. Each of these molecules
contain one variable region that is linked to two constant
regions. These constant regions allow primer binding during
an amplification step. In-gel amplification of this library results
in so-called polonies (polymerase colonies). During FISSEQ,
the polonies are denatured, and sequencing primers hybridize
to the template (Figure 3). Next, sequencing is performed by
different cycles in which single fluorescent nucleotides are added
and imaged (Mitra et al., 2003). In 2014, the next-generation
of FISSEQ was developed (Lee et al., 2014). This technique
allows the use of both fresh-frozen (FF) tissue and formalin-
fixed paraffin-embedded (FFPE) tissue. First, the fixed tissue is
tagged with random hexamers, followed by reverse transcription
and cDNA amplification. Next, these cDNA amplicons are cross-
linked in situ and sequenced. Each base is visualized in one
color, resulting in certain barcodes that can be mapped to the
genome. There is no need to select candidate genes as this method
captures all of the mRNA and thus can localize the RNA whole
transcriptome. Other advantages of this technology are high
sensitivity and high throughput. Furthermore, FISSEQ can be
applied to intact cells and tissues, avoiding sectioning. However,
low-abundant targets are not detected by FISSEQ, as the mRNA
to cDNA conversion efficiency is limited (Lee et al., 2014, 2015).
In situ sequencing (ISS) was first described in 2013 (Ke et al.,
2013). The ISS procedure starts with reverse transcription of
mRNA to cDNA, followed by the hybridization of padlock probes
to the cDNA strand (Figure 3). Two approaches were developed:
gap-targeted sequencing and barcode-targeted sequencing. Both
approaches are followed by rolling-circle amplification and
sequencing by ligation, which makes it possible to sequence
small RNA fragments, within cells, and tissue sections. For gap-
targeted sequencing, one extra DNA polymerase step has to be
taken to fill the gap. The barcode-targeted sequencing approach
uses a padlock probe containing a barcode. During sequencing
by ligation, anchor primers are hybridized next to the targeted
sequence. Then, sequencing probes containing a fluorescent label
for one specific nucleotide bind to the anchor primers, allowing
the decoding of the gap sequence or the barcode (Ke et al., 2013).
In 2017, CARTANA commercialized ISS (barcode-targeted
sequencing approach) promising the simultaneous detection of
600 target genes. To increase the detection sensitivity for low-
abundant targets, multiple probes could be assigned to one target,
as was performed by Chen et al. for the microglial gene Itgam
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(Chen et al., 2020). In this study, ISS was used as a validation
method for spatial transcriptomics (ST), discussed below. ISS
was performed in a mouse model for Alzheimer’s disease to
determine if certain gene expression patterns could be localized
to specific cell types. They observed that microglia were the
main cell type responsible for expressing plaque-induced genes.
Eighteen of these plaque-induced genes overlapped with disease-
associated microglia (DAM) genes, which are also increased in
MS mouse models (Krasemann et al., 2017). ISS thus could
bring us new insights in MS pathology at a spatial single-cell
level. Moreover, low-abundancy problems could be solved using
multiple probes for one target.
Spatial ex situ Sequencing Techniques
Another approach to profile gene expression while retaining
spatial tissue information is spatial transcriptomics. ST was
first reported by Ståhl et al. (2016) and was improved by
10X Genomics in 2019 under the name “10X Visium” with
an increase in resolution. ST and 10X Visium make use of
special glass slides containing barcoded mRNA-capturing probes
printed in spots (Figure 3). All probes within one spot have
the same spatial barcode. First, samples are fixed on the glass
slide followed by hematoxylin and eosin (HE) staining and
imaging. Next, the tissue is permeabilized, which allows RNA
binding to the barcoded mRNA-capturing probes. This barcode
will be incorporated into the cDNA during reverse transcription.
The last step is library preparation and sequencing (Salmén
et al., 2018). ST and 10X Visium thus combine histology and
transcriptomics. An advantage of these techniques is that prior
knowledge of certain genes is not needed, as the 200 million
probes within a spot capture all of the mRNA in a tissue section.
However, the resolution does not yet approach the single-cell
level; the spots have a diameter of 100 µm (ST) or 55 µm
(10X Visium), and thus, multiple cells (depending on the tissue
type) are captured within each spot. The use of ST could be
of interest when analyzing different lesion types in MS. Several
studies already analyzed gene expression profiles of different
MS lesions, for example by bulk-RNA sequencing or single-cell
sequencing (Mycko et al., 2004; Elkjaer et al., 2019; Schirmer et al.,
2019). ST/10X Visium retains spatial information by staining and
imaging the tissue prior to tissue permeabilization. The spatial
barcode makes it possible to map gene expression patterns back
to their original location within the tissue section (Figure 3).
ST/10X Visium thus could add insights in spatial gene expression
profiles within the lesions itself or where the lesion transitions to
NAWM. A limitation of ST technology is that it is not suitable for
detection of low abundant targets, which is true for the majority
of microglial genes. Furthermore, only a relatively small tissue
section can be analyzed, as the mRNA-capturing probes lay in
squares of around 6 × 6 mm (ST) or 8 × 8 mm (10X Visium)
(Salmén et al., 2018).
A similar approach to ST/10X Visium is slide-seq, which was
developed in 2019. Slide-seq also uses glass slides containing
barcoded beads (Figure 3). These barcodes refer to a position on
the glass slide, which makes it possible to map gene expression
back to the imaged tissue section. However, in contrast to
ST/10X Visium, adjacent tissue sections are used for staining
and imaging, which could decrease the specificity when including
heterogeneous tissues. A major advantage of slide-seq is that the
barcoded beads have a resolution of 10 µm and can detect gene
expression with approximate single-cell resolution (Rodriques
et al., 2019; Asp et al., 2020). Furthermore, it takes about 3 h
to process the tissue, while this is around 8 h for 10X Visium
(for both techniques, this excludes imaging and quality control
time) (Rodriques et al., 2019). However, slide-seq is not yet
commercially available.
In summary, in the last few decades, different techniques
have been developed that make use of spatial gene expression
analysis. Methods that allow for spatial detection could provide
information about heterogeneity of cells and genes within
tissue sections, interactions between cells, and their function
and cellular composition. These findings could contribute to
novel insights in the underlying mechanisms of pathologies,
which are crucial in the process to identify novel therapeutic
targets. Depending on the study and its aim, it is important to
keep in mind the advantages and disadvantages of the spatial
technologies as sensitivity, resolution, and throughput differ





Both high-resolution transcriptomics and spatial detection
methods measure RNA levels. In addition, high-resolution
transcriptomics requires isolation of microglial cells. It
remains largely unclear how preanalytical factors such as
RNA quality, postmortem delay (PMD), and microglia isolation
methods exactly influence the microglial transcriptome.
These preanalytical factors vary between labs, and standard
procedures are lacking. In order to obtain a pure microglia
cell population, mechanical or enzymatic tissue dissociation
methods are required, followed by FACS or magnetic bead
sorting. Alternatively, in mice, microglia-specific RNA molecules
can be captured using RiboTag or PAPERCLIP technologies
(Hwang et al., 2017; Haimon et al., 2018). Analysis of microglia
gene expression by RiboTag identified that changes can occur
upon microglia isolation, where proinflammatory genes are
significantly upregulated due to dissociation at 37◦C (Haimon
et al., 2018). The PAPERCLIP technology has the advantage that
microglia cells represent a more native state because alternative
polyadenylation does not affect microglial gene expression
profiles (Hwang et al., 2017). Furthermore, microglia can
be obtained via LCM-guided single-cell isolation. However,
the microglia transcriptome appeared to be different when
comparing LCM- and FACS-isolated microglia, where LCM-
isolated microglia are not a pure microglial population, since
50% neuronal and oligodendroglial transcripts were also
detected (Solga et al., 2015). In mice, tissue dissociation steps
can be skipped using the genetic cTag-PAPERCLIP or Ribotag
model for microglia isolation, which more accurately reflects
the microglia transcriptome (Hwang et al., 2017). Of note,
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spatial detection methodologies are always independent of
microglia isolation procedures, therefore reflecting in vivo
microglia more accurately; of course, the effect of PMD still
remains. The Netherlands Brain Bank isolated microglia cells
of 100 donors, including MS donors who, in general, have a
longer PMD compared to controls, since an extended autopsy
protocol was applied for MS donors using MRI to select lesions.
RNA isolation and quantitative PCR (qPCR) were performed
on microglial cells isolated from these donors. Surprisingly,
there was no effect of PMD on microglial cell yield, while
cerebrospinal fluid pH had a positive correlation with the
yield (Mizee et al., 2017). Next, a high RNA integrity number,
reflecting no RNA degradation within the tissues, is an important
factor to generate reliable and reproducible gene expression
datasets. In brain tissue, RNA quality of controls has been
reported to be significantly higher than in disease conditions,
but overall RNA quality was independent of PMD up to 36 h
(White et al., 2018). In addition, RNA quality is independent of
storage time (White et al., 2018; Shah et al., 2019). RNA quality
differences within one dataset might mask biologically relevant
information. Computationally, it is possible to correct for RNA
quality using a linear model framework (Gallego Romero et al.,
2014). However, tissue selection based on RNA quality is an
important step prior to downstream analysis. To summarize,
RNA quality and microglia isolation procedures have larger
effects on gene expression than the PMD. However, only a
minimal amount of studies investigated the effect of PMD on
gene expression; so far, these studies did not use high-throughput
gene expression technologies.
PROTEOMIC STUDIES TO DECODE
CELLULAR HETEROGENEITY
Proteomics is the study of the entire proteome in a cell,
tissue, or organism. The proteome is dynamic and subject
to posttranslational modifications, protein–protein interactions,
synthesis, and degradation (Chandramouli and Qian, 2009;
Aslam et al., 2017). Techniques to analyze specific proteins
are Western blotting and enzyme-linked immunosorbent assay
(ELISA); however, these allow the analysis of just a few proteins
at a time (Aslam et al., 2017). Coons et al. (1941) were the first to
use IHC in their study for the spatial detection of protein epitopes
within a tissue section. Already in the 1990s, HLA-DR stainings
were performed to study antigen representation in NAWM from
MS patients compared to controls (Hayes et al., 1988). IHC is a
technique that is still used; however, over the years, new methods
have been developed for protein detection that allow a higher
throughput or are combined with transcriptomics.
One protein detection technique with a higher throughput
is mass cytometry. This technique is a combination of flow
cytometry and mass spectrometry. Instruments to measure mass
cytometry are cytometry by time-of-flight (CyTOF), CyTOF2,
and the most recent one, Helios. Both sensitivity and throughput
increased with each generation of instruments. Mass cytometry
requires single-cell suspensions, which are incubated in a pool
of antibodies conjugated to a unique, stable heavy-metal isotope
(Figure 3). These isotopes are used as reporters, capable of
measuring the gene expression of specific targets. Next, nebulized
droplets are introduced into the inductively coupled argon
plasma (ICP). Here, ions are liberated, and cells are atomized.
Ions are filtered in the quadripole, which allows only the heavy-
metal reporter ions to be distinguished by their variation in
mass and to be quantified by CyTOF(2) or Helios. Up to
45 parameters can be detected, which is a large improvement
compared to the 8–12 parameters that can be detected by flow
cytometry (Bendall et al., 2012; Spitzer and Nolan, 2016). Mass
cytometry does not only allow for the detection of proteins
and their expression levels; also posttranslational modifications
and proteolytic products can be determined. For example, the
technique is able to measure phosphorylated (activated) states
of proteins, which could provide insights in cellular behavior
(Spitzer and Nolan, 2016). Mass cytometry thus contributes
to the decoding of cellular heterogeneity. Ajami et al. (2018)
used cell cytometry to characterize myeloid populations in EAE
and other models for neurodegenerative diseases [Huntington’s
disease (HD) and amyotrophic lateral sclerosis (ALS)]. Using
CyTOF, Ajami et al. (2018) identified two CD11b+ myeloid
populations in the healthy brain, while an extra CD11b+
myeloid population was detected in the CNS of EAE mice
and in HD and ALS models. The first population (population
A) was characterized by a CD317+ MHC-II–CD39lowCD86-
profile; the second population (population B) was CD317+
MHC-II–CD39hiCD86+; and the third (population C) was
CD317+MHC-II+CD39hiCD86+, indicating that populations
B and C consisted of activated microglia. Furthermore, CD11c
was only expressed by population C. During EAE progression,
population C expanded, while in chronic EAE and in the
recovery phase, a decrease in the number of cells in population
C was observed. CyTOF revealed coexpression of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and TNFα in
most of the cells in population C during EAE onset and peak
of disease, while in HD and ALS models, the percentage of
cells expressing these cytokines was low or absent. Another
interesting observation was an increase in the expression of the
signaling molecules pCREB and pMAPKAPK2 in populations
B and C during the onset and subsequently during the
peak of EAE. In addition, CyTOF revealed that CD49d (α4
integrin) and CD49a (α5 integrin) were only expressed on
peripheral monocyte populations and not on CNS resident
myeloid populations. Blocking CD49a expression attenuated
EAE, highlighting the potential of CD49a as a therapeutic
target (Ajami et al., 2018). This study confirms that mass
cytometry is an interesting method to consider when studying
cellular heterogeneity, as it is a single-cell method that can
distinguish different populations based on (co)expression levels
of transcription factors, signaling molecules, cytokines, and other
proteins in a specific cell type.
Mass cytometry has a throughput of around thousand cells
per seconds, which is much lower compared to flow cytometry,
making the technique time consuming. Furthermore, as cells
are ionized and atomized during mass cytometry and thus fully
shattered, it is not possible to sort cells and collect them for
further analysis (Bandura et al., 2009; Spitzer and Nolan, 2016).
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New methods, such as cellular indexing of transcriptomes
and epitopes by sequencing (CITE-seq) and RNA expression and
protein sequencing assay (REAP-seq), have been developed that
measure both cell-surface protein and gene expression levels in
the same individual cell (Figure 3). Both techniques use DNA-
barcoded antibodies to tag proteins of interest. These barcodes
are unique oligonucleotides that contain an amplification primer
and sequencing handle. After cell lysis, reverse transcription, and
preamplifications steps, library preparation can be performed
followed by single-cell sequencing (Peterson et al., 2017;
Stoeckius et al., 2017). The difference between the two techniques
is the way the antibody is conjugated to the DNA sequence.
In CITE-seq, antibodies are conjugated to streptavidin, which
is non-covalently bound to the oligonucleotide, while in REAP-
seq, the antibody and oligonucleotide are conjugated by covalent
bonds (Peterson et al., 2017; Todorovic, 2017). At the moment,
both techniques are not able to detect intracellular proteins;
however, due to the conjugation of antibody and barcode by
covalent bonds, REAP-seq has potential for intracellular labeling
of proteins in the future (Peterson et al., 2017). At present, up to
82 antibodies can be multiplexed at the same time, although it is
likely that this number will increase as CITE-seq and REAP-seq
are not obstructed by signal collision as is the case in flow and
mass cytometry (Stoeckius et al., 2017).
Taken together, proteomic studies are of importance when
investigating underlying mechanisms of diseases, as mRNA
gene expression levels do not always reflect protein expression
levels due to posttranslational modifications, protein trafficking,
localizations, and protein–protein interactions. Mass cytometry
could provide insights, as it is able to determine posttranslational
modification and proteolysis products. On the other hand,
since REAP-seq and CITE-seq can measure cell-surface
protein and gene expression levels in parallel, they could also







Wide availability of (novel) technologies makes it challenging
to choose the most appropriate method to apply to answer
specific scientific questions. Here, we provide an overview of
important properties per technology, which can facilitate the
decision-making process (Table 1 and Supplementary Figure 1).
All sequencing-based technologies are unbiased, facilitating novel
discovery, since there is no need to preselect candidate genes.
High sensitivity is a major advantage of low-resolution
transcriptomics. Increasing resolution and throughput generally
decreases sensitivity (20%) due to a lower library complexity,
which is a major drawback of high-resolution transcriptomics,
and only allows the detection of variations in the most abundantly
expressed genes. Sequencing methodologies differ in sequencing
of whole transcripts (long reads) or sequencing of a small part
of the transcript: the 3′ or 5′ end (short read). Short-read
sequencing is not suitable to detect splicing variants and has
a higher error rate, making annotating genes to the genome
more complex compared to long-read sequencing. Therefore,
long-read sequencing is more sensitive compared to short-
read sequencing. However, in terms of examining heterogeneity
and identifying microglia subtypes, high resolution is absolutely
required. High-resolution transcriptomics is possible at the
single-cell or single-nucleus level. snRNAseq has certain
advantages above scRNAseq; first, nuclear RNA molecules can
be obtained from frozen archived tissue samples, which can be
very precisely classified for example into MS lesion types with
matching HLA-DR scores. Furthermore, cell isolation and sorting
is not required, which are the main factors causing cellular
stress, which in turn can slightly change the transcriptome.
Some cell subtypes are more vulnerable to cellular stress
than others; therefore, nuclear RNA most likely represents
a more reliable ratio of cell subtypes. Second, nuclear RNA
molecules reflect active transcription, which might result in
a more accurate view of the condition of interest. snRNAseq
of microglia or other less abundant cell types benefits from
enrichment strategies to obtain sufficient numbers for in-depth
analysis. So far, studies have used a direct microglial enrichment
strategy based on IRF8 sorting (van der Poel et al., 2019)
or an indirect strategy by selecting a NEUN/OLIG2 negative
population to select against major cell types of the brain:
neurons and oligodendrocytes (Gerrits et al., 2020). Both single-
cell and single-nuclei sequencing require extensive validation
experiments to prove the existence and functionality of the
detected subtypes, since spatial information is lacking.
Cell shape and localization often reflect functionality, which
is already an old concept in biology. Therefore, spatial detection
methods offer great possibilities to examine heterogeneity and
functionality at the same time in a region specific manner,
by using ex situ (spatial transcriptomics, slide-seq) or in situ
(FISSEQ, MERFISH, ISS) technologies, reviewed here (Lee, 2017;
Lein et al., 2017). However, can we obtain similar resolution
and throughput as in single-cell/single-nuclei sequencing? Not
at the moment. The resolution of ex situ spatial detection is
55 µM (1–10 cells/spot) for a commercially available method
from 10X Genomics (Visium), as resolution is limited by
printing distinguishable barcodes (Ståhl et al., 2016; Salmén
et al., 2018; Gregory et al., 2020). That level of resolution could
cause problems if your goal is to determine the contribution
of the microglial transcriptome for a specific condition or
disease, since microglia comprise only 10% of all brain cell
types and since specific microglial subtypes are expected to
represent an even smaller percentage. Compared to astrocyte
and oligodendrocyte populations, these subsets likely provide
too few RNA molecules to be detected and visualized in spatial
transcriptomics in the mouse brain (Figure 4). Solving this
issue would require higher resolution, higher sensitivity, and
better computational deconvolution strategies. In comparison,
slide-seq uses barcoded beads to increase the resolution to
10 µM (one to two cells/bead) and detection of genes is
unbiased, although standardized description of the protocol
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FIGURE 4 | Spatial gene expression of (A) astrocyte, (B) oligodendrocytes, and (C) microglia-cell-specific marker genes, visualized in sagittal anterior control mouse
brain. Dataset obtained from 10X Genomics.
is not available yet (Rodriques et al., 2019). Throughput of all
spatial detection methodologies is limited by imaging speed;
therefore, measuring the complete tissue section is often not
possible or very expensive. In situ spatial detection methods are
very suitable for regional validation of target genes in a cell-
specific manner. ISS by CARTANA (Ke et al., 2013; Maïno et al.,
2019) is a very promising and easy-to-use methodology, where
individual genes are targeted by barcoded padlock probes, which
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is a more sensitive methodology compared to unbiased in situ
approaches including FISSEQ (Lee et al., 2015). More specifically,
the sensitivity of ST (7%), ISS (10%), and FISSEQ (0,005%) are all
lower compared to single-cell or single-nuclei sequencing (20%).
Other disadvantages of ISS are limited throughput and limited
detected targets (up to 90 genes) restricted to predetermined
target genes, and the design of novel padlock probes is costly.
However, the next generation ISS allows detection of up to 600
genes and does not use padlock probes.
Proteomics technologies have some advantages above
transcriptomic technologies. Proteomics is generally easier to
apply because proteins are more stable than RNA molecules,
although this might not be true for all posttranslational
modifications. Most proteomics technologies are also cheaper
compared to transcriptomics; however, exceptions are, for
example, CyTOF, which requires the production of many
antibodies. mRNA expression does not always predict protein
expression levels in a cell. Therefore, proteomics could contribute
to important insights in cell functioning. This will be a major
advantage when the study goal is to find new effective drugs,
since most therapeutics target proteins and not the mRNA, which
makes proteomics crucial for drug development. For example,
with a proteomic strategy, Ajami et al. (2018) discovered CD49a
as a potential new drug target for MS. Furthermore, proteins
are often adapted with posttranslational modifications such as
phosphorylation, lipidation, and glycosylation, resulting in, for
example, active forms of a protein with slightly changed folding
or conformation. Proteomics technologies are able to distinguish
the phosphorylated (active) state of a protein, from the non-
phosphorylated (inactive) state (Spitzer and Nolan, 2016),
which is highly important for biological data interpretation
and cannot be detected with transcriptomics. High-throughput
proteomic methodologies, such as REAP-seq and CITE-seq, can
perform proteome and transcriptome analysis simultaneously,
which allows to compare the levels of both molecules in
one biological sample. Despite these major advantages, there
are also disadvantages to this type of proteomics technique;
often, not all proteins can be detected easily, and some
technologies can only detect extracellular and not intracellular
proteins. Moreover, protocols for proteomic methodologies
are not commercially available, thus requiring more skills to
robustly perform these technologies. Furthermore, proteomics
can often detect a lower number of targets simultaneously
compared to transcriptomics; however, this is expected to
increase in the future.
FUTURE PERSPECTIVES
The recent advances in high-resolution gene and protein
expression profiling of microglia in MS have contributed to the
identification of MS signatures in microglia subtypes; it makes
researchers aware of the heterogeneity present in MS tissues.
Future studies should take this heterogeneity into account by
analyzing the different lesion types and GM/WM independently.
This selective approach is likely to result in more information
about MS-associated microglia subtypes. Currently, specific
markers to isolate these MS-associated microglia subtypes
individually are lacking. The field would remarkably benefit
from isolating these disease-associated subtypes and perform
more functional assays in order to elucidate their exact role in
MS. Moreover, creating a landscape of cell (sub)type specific
datasets allows studying interactions between cell (sub)types, for
example ligand receptor mapping (Cabello-Aguilar et al., 2020).
Furthermore, it can help to identify the drivers behind spatial
heterogeneity; is this solely determined by the environment or
do cell intrinsic mechanisms also play a role? In the context
of MS, this information can be linked with genome-wide
association studies (GWAS), which provide information about
single-nucleotide polymorphisms (SNPs) associated with higher
MS risk (Patsopoulos et al., 2019).
Finally, to facilitate the extraction of biologically relevant
information from these large datasets, public platforms should
be generated to share datasets produced by different research
groups, stratified by disease, region, and cell (sub)types. Three
existing RNA sequencing databases are GOAD—now Brain-
sat (Holtman et al., 2015a), Brain RNA-seq (Zhang et al.,
2014), and Neuroexpresso (Mancarci et al., 2017), which can
be used to obtain glial-cell-type specific information. Currently,
region specific information is lacking in these databases. For
analysis of distinct regions, the mouse (Erö et al., 2018)
or human brain atlas (Sunkin et al., 2013) can be used
to annotate brain regions in spatial transcriptomics datasets.
The Allen Brain Atlas already extended their anatomic data
with genomic data, combining microarray, ISH, and MRI
datasets. Future databases should be extended with protein
and spatial information. The next step would be to integrate
such a database with information about chromatin states
associated with transcription regulation, such as chromatin
accessibility (ATAC-seq), specific histone marks (CHIP-seq), or
interactions within the genome and chromatin conformation
capture technologies (Hi-C, PLAC-seq). Recently, an MS study
by Factor et al. (2020) showed that this type of analysis can
result in valuable information, as this study showed that the
enhancer elements regulating BRD3 and HEXIM1 are directly
associated with an MS risk gene and that these enhancers
were dysregulated in MS, contributing to remyelination failure.
Region and cell (sub)type specific profiling, as reviewed here,
can be applied to diseases where cellular heterogeneity is an
important factor in disease progression. In addition, it would
allow for the identification and targeting of (pathogenic) cellular
subsets. These specific pathogenic subtypes can potentially be
reprogrammed into a homeostatic or more beneficial state
via targeted drugs or treatments. Thus, the use of these
novel technologies will result in better insights in MS disease
pathogenesis and potentially contribute to the identification of
novel targets to treat MS.
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Jäkel, S., Agirre, E., Mendanha Falcǎo, A., van Bruggen, D., Lee, K. W.,
Knuesel, I., et al. (2019). Altered human oligodendrocyte heterogeneity
in multiple sclerosis. Nature 566, 543–547. doi: 10.1038/s41586-019-
0903-2
Jha, M. K., Jo, M., Kim, J. H., and Suk, K. (2019). Microglia-astrocyte crosstalk:
an intimate molecular conversation. Neuroscientist 25, 227–240. doi: 10.1177/
1073858418783959
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